Dear Editors,
Thank you for the opportunity to comment upon the matters raised by Professor Dasgupta and multidisciplinary colleagues. It is encouraging to hear that this team are a beacon of good practice in the monitoring and assessment of paediatric ototoxicity related to cancer therapy. The protocol described is congruent with existing international guidelinesReference Clemens, van den Heuvel-Eibrink, Mulder, Kremer, Hudson and Skinner1 and a forthcoming protocol endorsed by the International Society of Paediatric Oncology.
Our studyReference Brown, Caimino, Benton and Baguley2 sought to determine the present situation regarding the assessment of hearing, tinnitus and imbalance across specialist paediatric cancer centres in the UK. We found wide variations in protocols and practice (and, by implication, resources); this situation is far from ideal.
We agree with Professor Dasgupta and colleagues that interdisciplinary working (including oncology, otology and audiology) is urgently needed in this area, both to determine national protocols and to ensure well-resourced and consistent implementation in everyday clinical practice.
